Joachim Rothe
General Partner @ EQT Life Sciences
Munich, Germany
Joachim Rothe is a Series B investor at EQT Life Sciences in Munich focused on Biotechnology and Health Care. Joachim (JR) Rothe, PhD, joined LSP in 2002. He became a Partner and co-owner of the firm in that same year. His prime focus and responsibility within LSP is to invest in unlisted securities and the general management of the firm. Prior to joining LSP, Joachim was the Managing Director of MPM Capital Germany, a US healthcare investment firm,where he rose to head up their European investment franchise. Previously, he worked at McKinsey & Company in Germany and at Hoffmann-La Roche in Switzerland. Joachim brings a strong scientific background and in-depth knowledge of the pharmaceutical and biotechnology industries to the LSP team. He has been appointed a Director of a large number of companies, all of which he has helped to grow by leveraging his scientific expertise, pharmaceutical experience and global networks. Among others, Joachim is currently a Director at Atlas Genetics, a UK diagnostic company developing ultra-rapid point-of-care tests for a range of infectious diseases. Joachim obtained a Master’s degree in Biochemistry from the Free University in Berlin and a PhD in Molecular Immunology from Freiburg University. His thesis was supervised by Georges Köhler, a Nobel laureate in Medicine. Joachim has authored numerous articles in leading scientific publications, including Nature. Joachim lives in Munich with his wife and two children.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries Joachim Rothe invests in
Stages Joachim Rothe invests in
Countries Joachim Rothe invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 6 (43%)
- Health Care 4 (29%)
- Medical 3 (21%)
- Mobile 1 (7%)
- Genetics 1 (7%)
Stage
- Series B 4 (29%)
- Series A 2 (14%)
- Series C 2 (14%)
- Series D 1 (7%)
- Series E 1 (7%)
Country
- Germany 2 (14%)
- Spain 1 (7%)
- France 1 (7%)
- Switzerland 1 (7%)
- United States 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Binx Health is creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer mobile offerings, the company is redefining “convenient care” for the modern consumer | $65M / Series F / Apr 02, 2024 | ||
| DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results. | $165M / Series C / Oct 26, 2021 | ||
| Innovative Molecules develops drugs designed to treat Herpes simplex-induced diseases. | $24.4M / Series A / Jun 09, 2021 | ||
| Binx Health is creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer mobile offerings, the company is redefining “convenient care” for the modern consumer | $104M / Series E / May 27, 2021 | ||
| DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results. | $50M / Series B / Jul 29, 2020 | ||
| DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results. | $38.5M / Series B / May 16, 2019 | ||
| Nouscom is a developer of an immunotherapy platform that aims to create modified viral vector vaccines for cancer treatment. The company's platform makes use of a portfolio of engineered viral vectors that have been optimized for the efficient expression of long strings of tumor neoantigens. It also includes a toolkit for inducing broad andpotent antitumor T-cell responses, allowing patients to boost cancer-specific cellular immunity. | $48.8M / Series B / Nov 06, 2017 | ||
| Binx Health is creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer mobile offerings, the company is redefining “convenient care” for the modern consumer | $35M / Series D / Jan 23, 2017 | ||
| Luxendo will manufacture and sell advanced Single Plane Illumination Microscopes (SPIM) originally developed at EMBL by Lars Hufnagel and his team. SPIM is a rapidly emerging technology that combines optical sectioning with multiple-view imaging to observe tissues and living organisms with impressive resolution. Unlike the conventional techniquesof widefield and confocal fluorescence microscopy, the light sheet technique illuminates on the region surrounding the focal plane of the detection objective in a twin objective configuration. | $8.5M / Series A / Jan 12, 2017 | ||
| Luxendo will manufacture and sell advanced Single Plane Illumination Microscopes (SPIM) originally developed at EMBL by Lars Hufnagel and his team. SPIM is a rapidly emerging technology that combines optical sectioning with multiple-view imaging to observe tissues and living organisms with impressive resolution. Unlike the conventional techniquesof widefield and confocal fluorescence microscopy, the light sheet technique illuminates on the region surrounding the focal plane of the detection objective in a twin objective configuration. | $6.9M / Series A / Oct 14, 2015 | ||
| See all 14 investments → | |||
Co-Investors
About EQT Life Sciences
EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.
EQT Life Sciences Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Christoph Broja
Partner
|
|||
Fouad Azzam
General Partner
|
|||
|
Joachim Rothe
General Partner
|
|||
Clemens Van Blitterswijk
Founder of LSP Health Economics Fund
|
|||
Daniela Begolo
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Joachim Rothe invest in?
Joachim Rothe invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 14 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Joachim Rothe?
Public channels for Joachim Rothe include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Joachim Rothe last invest?
The most recent investment recorded for Joachim Rothe closed in Apr 2024. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
